IBEX Technologies Inc.·Healthcare
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.

IBEX Limited is pivoting from traditional BPO to HealthTech, leveraging AI and offshore labor to drive higher margins and growth. HealthTech segment grew 35% YoY, now 17.4% of revenue, with management targeting $100M by year-end, signaling a strategic shift to high-profit sectors. Q2 2026 revenues rose 16.7% YoY to $164.2M, with adjusted EBITDA margin improving to 12.6% due to cost efficiencies and segment mix.

IBEX Limited (IBEX) Q2 2026 Earnings Call Transcript

WASHINGTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”), a leading provider in global business process outsourcing and end-to-end customer engagement technology solutions, today announced financial results for its second fiscal quarter ended December 31, 2025.

WASHINGTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”) (Nasdaq: IBEX), a leading global provider of business process outsourcing (BPO) and AI-powered customer engagement technology solutions, today announced it will report second quarter 2026 financial results after the market close on Thursday, February 5, 2026. Management will host a conference call and webcast to discuss the Company's financial results, recent developments, and business outlook at 4:30 p.m. ET.